A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

Conclusion
These indirect comparisons of LCZ696 with a putative placebo show that the strategy of combined angiotensin receptor blockade and neprilysin inhibition led to striking reductions in cardiovascular and all-cause mortality, as well as heart failure hospitalization. These benefits were obtained even though LCZ696 was added to comprehensive background beta-blocker and mineralocorticoid receptor antagonist therapy.

Source: European Heart Journal - February 14, 2015 Category: Cardiology Authors: McMurray, J., Packer, M., Desai, A., Gong, J., Greenlaw, N., Lefkowitz, M., Rizkala, A., Shi, V., Rouleau, J., Solomon, S., Swedberg, K., Zile, M. R., Andersen, K., Arango, J. L., Arnold, M., Belohlavek, J., Bohm, M., Boytsov, S., Burgess, L., Cabrera, W. Tags: Heart failure/cardiomyopathy Source Type: research